STOK STOKE THERAPEUTICS INC US FDA Inspections 8-K Filing 2024 - FDA Breakthrough Designation Stoke Therapeutics announced that it received Breakthrough Therapy Designation from the FDA for its drug zorevunersen, which shows significant reductions in seizure frequency for Dravet syndrome patients, with an 87% median reduction at month eight of treatment.Get access to all SEC 8-K filings of the STOKE THERAPEUTICS INC